ReviewInternational journal of molecular sciences2022
Advanced Glycation End Products: A Sweet Flavor That Embitters Cardiovascular Disease.
Review in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.
- Advanced Glycation End Products and Health: A Systematic Review.Annals of biomedical engineering · 2024Pooled it
- BMI-Dependent Modulation of the Soluble RAGE-Sirtuin-1 Axis by Coffee Type in Coronary Artery Disease.Nutrients · 2026Article
- Article
- Hemoglobin glycation index and renal progression in patients with type 2 diabetes: a 5-year cohort study.Endocrine · 2026Article
- Dietary Advanced Glycation End Products and Cardiovascular-Kidney-Metabolic Complications.Clinical journal of the American Society of Nephrology : CJASN · 2026Review
- The predictive value of glycated albumin and hemoglobin A1c for all-cause and cardiovascular mortality in chronic kidney disease patients.Diabetology & metabolic syndrome · 2026Article
- Cross-talk between lipopolysaccharide tolerance and AGEs in the regulation of macrophage inflammation and cholesterol efflux.Frontiers in immunology · 2026Article
- Diabetes Mellitus and Lipoprotein(a): A Determinant Interaction in Micro- and Macrovascular Damage.International journal of molecular sciences · 2025Review
- SGLT2 Inhibitors in the Management of Cardio-Renal-Metabolic Syndrome: A New Therapeutic Era.Medicina (Kaunas, Lithuania) · 2025Review
- Association Between Serum Advanced Glycation End Products and Cardiovascular-Kidney-Metabolic (CKM) Syndrome: A 3-Year Longitudinal Cohort Study (2019-2022).Journal of diabetes · 2025Article
- The Association Between the Hemoglobin Glycation Index and Cardiometabolic Diseases: A Mini-Review.Journal of clinical hypertension (Greenwich, Conn.) · 2025Review
- Association between serum short-chain fatty acid levels and the risk of all-cause and cardiovascular disease mortality in Chinese patients undergoing maintenance hemodialysis: a retrospective cohort study.Clinical kidney journal · 2025Article
- Association between glycation gap and impaired cardiorespiratory fitness: evidence from American adults.BMC cardiovascular disorders · 2025Article
- Review
- Association of hemoglobin glycation index with clinical outcomes in patients with coronary artery disease: a prospective cohort study.Diabetology & metabolic syndrome · 2024Article
- Galectin-3 protects distal convoluted tubules in rhabdomyolysis-induced kidney injury.Pflugers Archiv : European journal of physiology · 2024Article
- Association between Mediterranean Diet and Advanced Glycation End Products in University Students: A Cross-Sectional Study.Nutrients · 2024Article
- Aging and "Age-Related" Diseases - What Is the Relation?Aging and disease · 2024Review
- The RAGE Axis: A Relevant Inflammatory Hub in Human Diseases.Biomolecules · 2024Review
- Liquid Chromatography with Tandem Mass Spectrometry Analysis of Carboxymethyl Lysine in Indonesian Foods.Molecules (Basel, Switzerland) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 1 country.
Funding
Abstract
Epidemiological studies demonstrate the role of early and intensive glycemic control in the prevention of micro and macrovascular disease in both type 1 and type 2 diabetes mellitus (DM). Hyperglycemia elicits several pathways related to the etiopathogenesis of cardiovascular disease (CVD), including the generation of advanced glycation end products (AGEs). In this review, we revisit the role played by AGEs in CVD based in clinical trials and experimental evidence. Mechanistic aspects concerning the recognition of AGEs by the advanced glycosylation end product-specific receptor (AGER) and its counterpart, the dolichyl-diphosphooligosaccharide-protein glycosyltransferase (DDOST) and soluble AGER are discussed. A special focus is offered to the AGE-elicited pathways that promote cholesterol accumulation in the arterial wall by enhanced oxidative stress, inflammation, endoplasmic reticulum stress and impairment in the reverse cholesterol transport (RCT).
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.